To confirm our predictions in silico, HCT 116 (wild-type TP53) with p53 KD and HT-29 (wild-type KRAS) overexpressing KRAS were developed to test their roles in ferroptosis in CRC cells. The gene discussed is KRAS; the disease is colorectal carcinoma.